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Mechanism of action of novel NO-releasing furoxan derivatives
of aspirin in human platelets
1Catriona M. Turnbull, 2Clara Cena, 2Roberta Fruttero, 2Alberto Gasco, 3Adriano G. Rossi
& *,1Ian L. Megson
1Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh; 2Dipartimento di
Scienza e Tecnologia del Farmaco, Universita` degli Studi di Torino, Turin, Italy and 3MRC Centre for Inflammation Research,
Queen’s Medical Research Institute, University of Edinburgh, Edinburgh
1 Incorporation of a nitric oxide (NO)-releasing moiety in aspirin can overcome its gastric side
effects.
2 We investigated the NO-release patterns and antiplatelet effects of novel furoxan derivatives of
aspirin (B8 and B7) in comparison to existing antiplatelet agents.
3 Cyclooxygenase (COX) activity was investigated in purified enzyme using an electron
paramagnetic resonance-based technique. Concentration–response curves for antiplatelet agents7the
soluble guanylate cyclase inhibitor, ODQ (50 mM) were generated in platelet-rich plasma (PRP) and
washed platelets (WP) activated with collagen using turbidometric aggregometry. NO was detected
using an isolated NO electrode.
4 The furoxan derivatives of aspirin (B8, B7) and their NO-free furazan equivalents (B16, B15; all
100 mM) significantly inhibited COX activity (Po0.01; n¼ 6) in vitro and caused aspirin-independent,
cGMP-dependent inhibition of collagen-induced platelet aggregation in WP. B8 was more potent than
B7 (PRP IC50¼ 0.6270.1 mM for B8; 400789mM for B7; Po0.0001. WP IC50s¼ 0.670.1 and
62710 mM, respectively). The NO-free furazan counterparts were less potent antiplatelet agents (WP
IC50s¼ 5473 mM and 62710 mM, respectively; Po0.0001, B8 vs B16). Of the hybrids investigated,
only B8 retained antiplatelet activity in PRP.
5 NO release from furoxan–aspirin hybrids was undetectable in buffer alone, but was accelerated in
the presence of either plasma or plasma components, albumin (4%), glutathione (GSH; 3mM) and
ascorbate (50 mM), the effects of which were additive for B7 but not B8. NO generation from furoxans
was greatly enhanced by platelet extract, an effect that could largely be explained by the synergistic
effect of intracellular concentrations of GSH (3mM) and ascorbate (1mM).
6 We conclude that the decomposition of furoxan–aspirin hybrids to generate biologically active NO
is catalysed by endogenous agents which may instil a potential for primarily intracellular delivery of
NO. The blunting of the aspirin effects of furoxan hybrids is likely to be due to loss of the acetyl
moiety in plasma; the observed antiplatelet effects are thereby primarily mediated via NO release.
Compounds of this class might represent a novel means of inhibiting platelet aggregation by a
combination of NO generation and COX inhibition.
British Journal of Pharmacology (2006) 148, 517–526. doi:10.1038/sj.bjp.0706743;
published online 15 May 2006
Keywords: Nitric oxide; platelets; furoxan; nitroaspirin; thrombosis; antithrombotic
Abbreviations: AA, arachidonic acid; AUC, area under the curve; cGMP, cyclic 50-guanosine monophosphate; COX-1,
cyclooxygenase-1; CPH, 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine.HCl; DEA/NO, 2-(N,N-diethyami-
no)-diazenolate-2-oxide; DMSO, dimethylsulphoxide; DTNB, 5,50-dithio-bis(2-nitrobenzoic acid); EPR, electron
paramagnetic resonance; GSH, glutathione; NO, nitric oxide; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one;
PPP, platelet poor plasma; PRP, platelet-rich plasma; sGC, soluble guanylate cyclase; TFA, trifluoroacetic acid;
WP, washed platelets
Introduction
Aspirin is a nonsteroidal anti-inflammatory drug that has long
been used as a prophylactic against thrombotic coronary
events (ISIS-2, 1988; PHS-Committee, 1989; Manson et al.,
1991). It reduces cardiovascular risk, primarily through
irreversible inhibition of prostaglandin H synthase-1 (also
termed cyclooxygenase-1, COX-1)-mediated platelet aggrega-
tion (for review see, Patrono, 1994). Aspirin selectively and
irreversibly acetylates a serine residue (Ser 530) of COX-1
(Roth & Majerus, 1975; Roth et al., 1975; DeWitt & Smith,
1988). COX-1 inhibition results in reduced production of
thromboxane A2, a vital element in the induction of
irreversible platelet aggregation in response to stimuli such
as collagen (FitzGerald, 1991; Hamberg et al., 1975). The
anucleate nature of platelets makes them unable to synthesize
new proteins and replace inhibited enzyme; recovery of full
platelet activity only takes place as a function of platelet
turnover (Burch et al., 1978). Aspirin also acts to inhibit the*Author for correspondence; E-mail: ian.megson@ed.ac.uk
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formation of thrombin (Kessels et al., 1994; Szczeklik et al.,
1992), a unique action that also prevents platelet aggregation
and impacts on the coagulation pathway. Taken together,
these properties offer a degree of platelet selectivity in the
action of aspirin.
Unfortunately, gastrointestinal disorders, including ulcera-
tion, are a common side effect of aspirin, limiting its use
(Cameron, 1975; Wallace, 1997; Tramer et al., 2000; Seager &
Hawkey, 2001). The effect is due to inhibition of prostaglan-
dins that normally protect the gastric mucosa (Whittle, 1977;
Robert et al., 1979; Schoen & Vender, 1989; Wallace, 1997).
Aspirin esters containing a nitric oxide (NO)-donor nitrooxy
function (e.g. NCX4016) are thought to overcome the gastric
side effects through the protective actions of drug-derived NO.
NO increases blood flow in the gastric mucosa, promoting
repair and removal of toxins (Wallace & Miller, 2000). NO
also increases secretion of protective gastric mucus (Brown
et al., 1993) and is thought to promote healing of gastric
ulcers by promoting angiogenesis (Ma & Wallace, 2000).
Alternatively, the protective effects of NO aspirin could be
due to masking of the aspirin carboxylic acid moiety by the
ester function (Rainsford & Whitehouse, 1976; Cena et al.,
2003).
While NO hybrids of aspirin were primarily designed to
protect against damage to the gastric mucosa, there may be
additional benefits of drug-derived NO through its many
protective effects in the vascular system. NO is a powerful
endogenous vasodilator (Palmer et al., 1987) which acts to
keep the vasculature in an active state of dilatation by
stimulating cGMP-mediated relaxation of vascular smooth
muscle cells. NO also opposes the adherence of monocytes to
the vessel wall (Tsao et al., 1997) and displays antithrombotic
actions through its ability to inhibit platelet adhesion
(Radomski et al., 1987b, c) and aggregation (Radomski
et al., 1987a; 1990; Pasqui et al., 1991). Inhibition of platelet
aggregation occurs primarily via stimulation of cGMP; the
platelet aggregation response to sodium nitroprusside has been
shown to be entirely cGMP dependent (Sogo et al., 2000).
However, cGMP-independent signalling mechanisms have also
been identified (Gordge et al., 1998; Trepakova et al., 1999;
Sogo et al., 2000; Homer & Wanstall, 2002; Crane et al., 2005).
Reduced NO synthesis or availability is heavily implicated as a
key factor in the initiation and progression of atherogenesis
(Anderson et al., 1995; Maxwell, 2002; Shaul, 2003).
The release at NO from NCX4016 and glyceryl trinitrate has
been reported to occur through identical mechanisms (Grosser
& Schroder, 2000). Platelets have a poor capability to release
NO from organic nitrates (Weber et al., 1996) and it is possible
that compounds such as NCX4016 will fail to show additional,
NO-mediated effects in platelets, at least in vitro. A new range
of drugs, in which a NO-donating moiety (furoxan group) is
joined by an ester linkage to the aspirin molecule (B8, B7;
Figure 1) appear to overcome the problem of gastric lesions
(Cena et al., 2003). However, the NO-release mechanism is
unlikely to require the same cellular machinery as that for
organic nitrates, suggesting that they might offer a degree of
NO-mediated antiplatelet effects to complement those of the
aspirin moiety.
In the present study, we investigated the mechanism of
action of two examples (3-cyanofuroxan-4-yl)methyl 2-acet-
oxybenzoate (B8) and (3-carbamoylfuroxan-4-yl)methyl 2-
acetoxybenzoate (B7); Figure 1), with different NO-releasing
properties (Cena et al., 2003) in human platelets in vitro. Here,
we characterize the NO-releasing and COX-inhibiting effects
of these novel furoxan derivatives of aspirin and compare their
actions to related antiplatelet agents.
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Figure 1 Structural formulae of furoxan hybrids (B8 and B7), furazan hybrids (B16 and B15) and the nitrooxy-ester NCX4016.
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Methods
Materials
2-(N,N-diethyamino)-diazenolate-2-oxide (DEA/NO; Axxora,
Nottingham, U.K.) was dissolved in 0.01M NaOH. 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; Cookson,
Langford, Bristol, U.K.) was dissolved in dimethylsulphoxide
(DMSO) and stored at 201C. Collagen was purchased from
Labmedics (Stockport, U.K.). 1-Hydroxy-3-carboxy-2,2,5,5-
tetramethylpyrrolidine. HCl (CPH) was purchased from
Axxora. All other chemicals were purchased from Sigma
(Poole, Dorset, U.K.). All nitro-aspirins were synthesized at
the Universita` degli Studi di Torino, as described (Cena et al.,
2003). Compound purity was assessed by high-performance
liquid chromatography before biological assays (over 98% for
all compounds; Merck Purosphere RP-18 column (Merck,
Darmstadt, Germany; 250 4mm2, 5mm particle size) eluting
with flow rate of 1mlmin1. Mobile phase consisted of 0.1%
aqueous trifluoroacetic acid (TFA) and acetonitrile containing
0.1% TFA in different ratios according with compounds
properties. The column effluent was monitored at 224/254 nm).
Compound identity was chemically confirmed by nuclear
magnetic resonance.
The nitro-aspirins were dissolved in DMSO, then diluted in
PBS to give a final concentration of 0.1% DMSO, which pilot
studies had determined not to affect platelet aggregation. No
precipitation of any drug was observed following dilution.
COX activity assay
The ability of novel and established compounds to inhibit
COX-1 was measured using an adaptation of a published
method (Schreiber et al., 1989). The assay relies on detection
of oxidizing free radicals produced as a by-product by the
peroxidase element of the COX enzyme. A spin-trapping
agent, CPH, was utilized to trap the short-lived radicals,
forming a stable adduct, 3-carboxy-proxyl. The assay makes
use of commercially available purified COX-1 from ovine
seminal vesicles (Sigma), pretreated with haematin for 5min.
The COX activity assay was performed at 371C in 1ml of
Tyrode’s buffer. In all, 100Uml1 purified COX-1 was
incubated with 3 nM haematin (5min, 371C) prior to the assay.
Aspirin, salicylic acid, a furoxan, a furazan, NCX4016
(100mM) or a vehicle control (DMSO, 1%) was added and
left to incubate for a further 10min prior to addition of the
spin-trap, CPH (1mM). At this point (time zero), a baseline
EPR measurement was taken (MS200, Magnettech, Germany.
Instrument settings: B0-field, 3356G; sweep width; 50G,
sweep time, 30 s; modulation amplitude, 1500mG; microwave
power, 20mW; microwave frequency, 9.3GHz). After 2min,
0.5mM AA (sodium salt) was added; EPR measurements were
made (50ml samples in micropipette tubes) after a further
1.5min incubation. The suicidal nature of COX-1 activation
means that the period of activation is complete withinB1min
of AA addition (as confirmed by pilot experiments).
The EPR results were corrected for any auto-oxidation of
spin-trap by subtraction of values recorded from a duplicate
sample run in the absence of AA. The intensity scale on the
y-axis of all graphs is an arbitrary scale based upon the area
under the curve (AUC) of the first derivative traces generated.
Results graphs show the timepoint 1.5min after the addition of
AA, as this was determined in pilot experiments to be the most
appropriate point at which to compare free radical generation
between control and furoxan-treated COX-1, given that spin-
adduct generation in response to AA had peaked – subsequent
adduct formation was at an equivalent rate in control and
AA-treated samples and was likely to be due to nonspecific
auto-oxidation of CPH.
Blood preparation
Peripheral venous blood was drawn from the antecubital fossa
of human volunteers aged 20–45 years who were non-smokers
and had not taken any platelet-active agents during the
previous 10 days. Blood was collected into tubes containing
3.8% sodium citrate and centrifuged at 200 g for 10min at
room temperature to obtain platelet-rich plasma (PRP). An
aliquot of PRP was further centrifuged at 1200 g for 10min
to obtain platelet-poor plasma (PPP). Washed platelets (WP)
samples were obtained by adding 300 ngml1 prostacyclin to a
2ml PRP sample before centrifuging at 1200 g for 10min.
Prostacyclin is commonly used at this concentration in this
type of study (Giuliano & Warner, 1999; Kobzar et al., 2001;
Crane et al., 2002). The effect of the prostacyclin is only
temporary due to its short half-life. The supernatant was then
discarded and the pellet resuspended in Tyrode’s buffer
(137mM NaCl, 2.7mM KCl, 1.05mM MgSO4, 0.4mM
NaH2PO4, 12.5mM NaHCO3, 5.6mM Glucose, 10mM HEPES
and 0.8mM CaCl in dH2O at pH 7.4). Prostacyclin
(300 ngml1) was again added before a second 10min
centrifugation (1200 g). Finally, the pellet was resuspended
in 2ml Tyrode’s buffer. For aggregation, platelet counts were
determined using a Coulter Ac.T 8 Hematology Analyzer
(Coulter Electronics, Luton, U.K.) and standardized to
250 109 l1 via dilution with PPP (PRP) or Tyrode’s buffer
(WP).
Aggregation
Inhibition of platelet aggregation was measured using optical
platelet aggregometry in a 4-channel aggregometer (Chrono-
Log, Labmedics, Stockport, U.K.) and data captured via
an analogue-digital converter (Maclab 4e, AD Instruments,
Sussex, U.K.). The instrument was calibrated such that the
difference in light transmission between test (PRP or WP) and
reference (PPP or Tyrode’s buffer, respectively) samples was
set to generate an 80mV signal. Typically, maximal aggrega-
tion caused B60mV change in signal. Briefly, PRP or WP
samples were equilibrated at 371C and stirred continuously at
1000 r.p.m. The samples were then treated with either B8
(10 nM–3mM), B7 (10mM–1mM), their respective NO-free
structurally related furazan derivatives, (4-cyanofurazan-3-
yl)methyl 2-acetoxybenzoate (B16; 10 nM–3 mM) or (4-carba-
moylfurazan-3-yl)methyl 2-acetoxybenzoate (B15; 10 mM–
1mM), NCX4016 (3 mM–0.3mM) or aspirin (acetylsalicylic
acid; 3 mM–1mM) for 10min before induction of aggregation
with supramaximal concentrations of collagen (2.5 mgml1).
The aggregation was then recorded turbidometrically over
5min against a reference PPP sample. Experiments were also
performed with the addition of 50 mM (supramaximal concen-
tration (Crane et al., 2005)) of the cGMP inhibitor ODQ
15min before addition of the drug. Aggregation was expressed
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as a percentage inhibition of control aggregation obtained with
2.5 mgml1 collagen.
NO release
Samples of PRP, PPP or Tyrode’s buffer (2ml) were incubated
in the aggregometer at 371C and stirred continuously at
1000 r.p.m. An isolated NO electrode (ISO-NO MARKII,
World Precision Instruments, Stevenage, U.K.), calibrated
using DEA/NO (0.1–1.6 mM), was introduced into the cuvette
and allowed to stabilize for 10min. B8 (100mM) or B7 (500mM)
was then added to the cuvette and the release of NO recorded
for 10min before addition of haemoglobin (10 mM) to scavenge
any generated NO. Experiments were also carried out in
Tyrode’s buffer74% albumin, with the addition of glu-
tathione (3 mM or 3mM), 750mM ascorbate before B8 or B7.
Ascorbate (1mM) was also used, but only in the presence of
10mM HEPES to buffer its acidic pH. The concentrations of
albumin, ascorbate and glutathione studied are all physiolo-
gically relevant. The detection limit for the electrode under the
conditions of the experiment was found to be B10 nM NO.
A platelet extract was also prepared from samples of PRP
and platelet count was determined using the Coulter Ac.T 8
Hematology Analyzer. The platelets were washed as above in
the presence of prostacyclin to obtain a platelet pellet. The
total platelet volume of the pellet was calculated by multi-
plying the number of platelets by the average platelet volume
(5.14 1015 l; obtained from the hematology analyzer). The
pellet was resuspended in 1ml of 0.5% Triton X in Tyrode’s
buffer for 1 h and the dilution of cell contents estimated using
the total platelet volume from the above calculation. This was
then homogenized by hand for 15min and centrifuged at
12,000 g for 10min to give a cell extract. B8 (100mM) or B7
(500mM) was added to 1ml of this supernatant in the assay
as described above.
A further set of experiments was carried out following
a 10min preincubation of the platelet extract with the thiol
alkylator, 5,50-dithio-bis(2-nitrobenzoic acid) (DTNB;
500 mM). The NO release from B8 (100mM) or B7 (500mM)
was then recorded as above. The samples were collected and
frozen (201C) and later used for thiol determination by
colorimetric analysis at 405 nm. Thiol levels of the extract
samples were determined from a standard curve created using
10 mM–30mM glutathione in 500 mM DTNB.
Statistics
All results are expressed as the mean7s.e.m. Concentration–
response curves were analysed by two-way analysis of variance
(two-way ANOVA). EPR data were analysed by 1-way
ANOVA and NO electrode data by two-tailed paired Student’s
t-test. Dunnett’s or Bonferroni post-tests were carried out
where appropriate. Po0.05 was considered to be statistically
significant.
Results
COX activity
Aspirin (100mM) significantly reduced the EPR signal gener-
ated by AA-stimulated purified COX-1 in Tyrode’s buffer
compared to a vehicle control (Figure 2; Po0.01; n¼ 8). A
significant inhibition of COX activity was also observed with
the furoxan–aspirins, B8 and B7 (100 mM; Po0.05 and Po0.01
respectively, n¼ 6). Even greater inhibition was demonstrated
with the NO-free furazan equivalents, B16 and B15 (100 mM,
Po0.01 for both, n¼ 6). The furazan compounds demon-
strated a significantly greater inhibition of COX than aspirin
(Po0.01). The nitrooxy-ester, NCX4016 (100mM) also abol-
ished COX activity (Po0.01, n¼ 6). Salicylic acid (100mM,
n¼ 6) failed to significantly inhibit generation of the spin-
adduct, as did the NO donor DEA/NO (100mM, n¼ 6;
Figure 2b).
Effect of aspirin, salicylic acid and NCX4016 on platelet
aggregation
Aspirin (3–300mM) caused concentration-dependent inhibition
of collagen-induced platelet aggregation in PRP and the effect
was enhanced in WP, but salicylic acid failed to show an
inhibitory effect, even at concentrations of 300mM (Figure 3;
n¼ 6–8). NCX4016 (3–300mM) had no effect on collagen-
induced platelet aggregation in PRP (Figure 3a; n¼ 6), but did
cause concentration-dependent inhibition of platelet aggrega-
tion in WP that was significantly more potent than aspirin
(Figure 3b; P¼ 0.002; n¼ 6). Responses to NCX4016 were
insensitive to the soluble guanylate cyclase inhibitor, ODQ
(15min preincubation; P¼ 0.88, NCX4016þODQ vs
NCX4016 alone in WP; Figure 3b).
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Figure 2 EPR-based COX-activity assay. (a) Typical 3-peak EPR
spectra obtained in the absence (control; COXþAA) and presence
of aspirin or hybrid compound (all 100 mM) after correction for
background autoxidation. EPR settings: B0-field, 3356G; sweep
width; 50G, microwave frequency, 9.3GHz; sweep time, 30 s;
modulation amplitude, 1500mG; microwave power, 20mW. (b)
Effect of aspirin, salicylic acid, furoxans, furazans and NCX4016 (all
100 mM) on EPR signals generated from COX-1 after treatment with
substrate (AA). In each case, drug incubations were for 10min prior
to the baseline EPR reading. Readings shown were taken 1.5min
after the addition of AA. *Po0.05, **Po0.01; one-way ANOVA
with Dunnet’s post hoc test vs control: n¼ 6–10. Values are
mean7s.e.m.
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Effect of B8 and B7 on platelet aggregation
B8 (10 nM–3 mM) caused concentration-dependent inhibition
of collagen-induced platelet aggregation in PRP at concentra-
tions B100-fold lower than for aspirin (B8 IC50 in
PRP¼ 0.6270.1mM; Figure 4a, (see Figure 3a for aspirin
effect)). ODQ significantly inhibited the responses to B8 in
PRP (Figure 4a; n¼ 6–8; Po0.0001), while the NO-free,
structurally related furazan derivative of B8 (B16; 10 nM–
1mM) was considerably less effective at inhibiting platelet
aggregation than B8 in PRP (Figure 4a; Po0.0001; n¼ 8).
The effects of B8 in PRP were largely mirrored in WP: B8
was found to be a powerful inhibitor of collagen-induced
aggregation (IC50¼ 0.670.1mM) and its actions were signifi-
cantly inhibited by ODQ (Figure 4b; Po0.0001; n¼ 6–8). B16
had a significantly greater inhibitory effect on platelet
aggregation in WP compared to PRP (IC50¼ 5473mM;
Figure 4b; Po0.0001; PRP B16 vs WP B16; n¼ 6–8).
B7 (10mM–1mM) was less effective than B8 and aspirin
at inhibiting collagen-induced platelet aggregation in PRP (B7
IC50¼ 0.3670.1mM). ODQ significantly inhibited the re-
sponse of B7 in PRP (Figure 4c; n¼ 6–7; Po0.0001). B15
was ineffective in PRP.
In order to make a direct comparison, concentrations
studied with WP were dictated by the PRP response curve.
B7 (10 mM–1mM) was considerably more effective in WP
(IC50¼ 2478mM) than PRP. The inhibitory effects of B7 in
WP were significantly attenuated by ODQ (P¼ 0.002, two-way
ANOVA; n¼ 6–7). In stark contrast to the findings in PRP,
B15 was found to be a powerful inhibitor of platelet
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Figure 4 Collagen (2.5 mgml1)-induced platelet aggregation in
PRP and WP. (a) Effect of B8 (7ODQ; 50 mM, 15min preincuba-
tion) and its NO-free equivalent, B16, on collagen-induced platelet
aggregation in PRP. Po0.0001 (B8þODQ vs B8 alone, n¼ 6–9).
(b) The effect of ODQ (50 mM) on responses to B8 in WP. Po0.0001
(þODQ vs B8 alone), n¼ 6–9. (c) Effect of B7 (7ODQ; 50 mM) and
its NO-free equivalent B15 on collagen-induced platelet aggregation
in PRP. ***Po0.0001, n¼ 6–7. (d) The effect of ODQ (50mM)
on the B7 response in WP. ***Po0.0001, n¼ 6–7. Values are
mean7s.e.m. Statistical analysis by two-way ANOVA.
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Figure 3 Collagen (2.5 mgml1)-induced platelet aggregation in
PRP and WP. (a) Effect of NCX4016, salicylic acid and aspirin on
collagen-induced platelet aggregation in PRP. ***Po0.0001, n¼ 6–
7. (b) The effect of the guanylate cyclase inhibitor ODQ (50 mM;
15min preincubation) on responses to NCX4016 in WP.
**P¼ 0.002, n¼ 6. Values are mean7s.e.m. Statistical analysis by
two-way ANOVA.
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aggregation in WP (B15 IC50 in WP¼ 62710mM); indeed, at
concentrations of 100 mM or more, it was as effective as B7
under these conditions.
NO release from furoxan–aspirin hybrids:
effect of endogenous antioxidants
Sample recordings of NO generation from B7 and B8 in the
presence and absence of GSH and ascorbate are shown in the
inserts to Figure 5a and c. Owing to the different profile of NO
release by the different drugs, it was established that AUC was
more representative of NO release than peak concentration in
these experiments; subsequent values quoted are all AUC over
the 10min incubation (mmolmin), but sample peak values are
also given for information.
NO release from NCX4016 (100mM) was undetectable in
Tyrode’s buffer, PRP or WP (n¼ 6–8 for each). Likewise, NO
release from the furoxans B8 and B7, was undetectable in
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Figure 5 NO release recorded over 10min from B8 (100 mM) or B7 (500 mM) in various media. (a) NO release from B8 in media
related to plasma conditions: Tyrode’s buffer was reconstituted with approximate plasma concentrations of the plasma constituents,
albumin (4%), GSH (3 mM) and ascorbate (50 mM). Inset shows typical 10min traces of NO release recorded via the NO electrode in
Tyrode’s buffer with or without ascorbate (1mM) and GSH (3mM). (b) Shows typical NO release from B8 in media related to
platelet conditions: Tyrode’s buffer 3 and 1mM are approximate intracellular concentrations of glutathione and ascorbate,
respectively; n¼ 6–7. GSH¼Glutathione. Ascorb¼ ascorbate. Values are mean7s.e.m. (c) Shows NO release from B7 in media
related to plasma conditions. Inset shows typical 10min traces of NO release from B7 recorded via the NO electrode in Tyrode’s
buffer with or without ascorbate (1mM) and GSH (3mM) (d) shows NO release from B7 in media related to platelet conditions.
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Tyrode’s buffer alone (Figure 5a and c). However, it was
detected in samples of PRP, WP, PPP or Tyrode’s buffer in the
presence of approximate plasma concentrations of albumin
(4%), GSH (3 mM) or ascorbate (50 mM; Figure 5b and d).
NO was released from B8 in platelet-containing samples
(PRP and WP; mean NO release¼ 33.272.9 and
33.072.5mmolmin, respectively, with both peaking at
B1.25 mM NO; Figure 5b), and in PPP (mean NO release for
B8¼ 21.072.8mmolmin, peak at B0.6mM NO; Figure 5a).
Reconstitution of Tyrode’s buffer with approximate plasma
concentrations of either albumin (4%), glutathione (3 mM) or
ascorbate (50 mM) enhanced NO generation from B8. A
combination of these three constituents failed to enhance
NO release from B8 beyond the effects seen with the individual
components alone (2.770.7mmolmin, peak atB0.040 mM for
GSH alone and B0.038 mM NO in the presence of plasma
concentrations of albumin, GSH and ascorbate; Figure 5a;
P¼ 0.78 vs GSH alone, P¼ 0.13 vs ascorbate alone, both
unpaired Student’s t-test).
Reconstitution of Tyrode’s buffer with approximately
intracellular concentrations of GSH (3mM) generated margin-
ally less NO from B8 (14.472.5mmolmin; Figure 5b; peak at
B0.124 mM NO) compared with samples containing platelets.
Ascorbate (1mM) in Tyrode’s buffer caused minimal NO
release from B8 (¼ 2.270.9mmolmin; Figure 5b; peak at
B0.004 mM NO), but a combination of GSH and ascorbate
caused a considerable increase in NO generation from B8
(247719mmolmin, n¼ 6, Figure 5b, Po0.0001 vs individual
components alone, unpaired Student’s t-test; peak at
B2.31 mM NO).
Relatively low levels of NO were released from B7 in PRP
and WP (1.670.4 and 3.870.7mmolmin, respectively; n¼ 6,
Figure 5d. Peaks atB0.085 and B0.120 mM NO, respectively)
despite the higher drug concentration used. Reconstitution of
the Tyrode’s buffer with approximate plasma concentrations
of either albumin (4%), glutathione (3 mM) or ascorbate
(50mM) enhanced NO generation from B7 and a combination
of these three constituents had an additive effect on the release
of NO from B7 (3.870.8mmolmin; peak at B0.295mM NO),
where release was equivalent to that seen in PPP (unpaired
Student’s t-test P¼ 0.628; Figure 5c).
Reconstitution of Tyrode’s buffer with approximately
intracellular concentrations of GSH (3mM) increased NO
release from B7 (8.571.1mmolmin; peak at B0.504 mM NO).
Ascorbate (1mM) in Tyrode’s buffer caused minimal NO
release from B7 (3.171.6mmolmin; peak at B0.004 mM NO),
but a combination of GSH and ascorbate caused a consider-
able increase in NO generation from B7 (4774mmolmin
n¼ 6, Figure 5d; peak at B0.642mM NO).
Effect of platelet extract on NO generation from B8
and B7
There was a relationship between the dilution factor of platelet
extract and the amount of NO released from both B8 and B7
(Figure 6a and b). NO generation by B8 (100mM) failed to
increase at platelet extract dilutions below B1 in 30, with
a maximum NO generation of B90mmolmin. Pretreatment
of platelet extracts with the thiol alkylator, DTNB (500 mM),
all but abolished NO generation.
A similar pattern was observed with B7 (500 mM), but the
amount of NO generated in the presence of platelet extracts
was 410-fold lower than from B8, despite the higher drug
concentration. In the case of B7, dilutions of platelet extract
lower than B1 in 75 failed to generate detectable NO, but
there was a direct relationship between NO generation and
dilution factor at dilutions of 1 in 75 to 1 in 25 (Figure 6b).
DTNB again showed a marked inhibitory effect on NO
generation in the presence of platelet extract. Colorimetric
analysis of DTNB-treated samples yielded intracellular total
reduced thiol concentrations of 2274mM (corrected for
dilution; n¼ 5).
Discussion
Our results show that two novel furoxan–aspirin hybrids drugs
effectively inhibit collagen-induced platelet aggregation and
the relative contribution of NO to the inhibitory effect was
dependent on the characteristics of the specific furoxan
involved. The potent effects of B8 were considered to be
largely NO dependent on account of the fact that the closely
related NO-free furazan, B16, had only a very weak antiplate-
let effect. B7 was a less potent inhibitor of aggregation than B8
but the effects were also primarily NO mediated in PRP, where
the furazan counterpart was largely ineffectual. However, in
WP, it was apparent that the antiplatelet activity of B7
comprised both NO-dependent and -independent components.
The existing nitrooxy ester, nitro-aspirin (NCX4016), was also
an effective antiplatelet agent in WP but the effects were
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Figure 6 A sample of WP was suspended in 1ml 0.5% Triton X
and then homogenized to release platelet extract before centrifuga-
tion to remove membrane fraction. The dilution factor on x-axis was
calculated by volume Triton X (1ml)/(number of platelets average
platelet volume). (a) NO release from 16 platelet extracts treated
with 100 mM B8. The triangles show samples treated in the same way
but with a 10min preincubation with 500 mM DTNB before addition
of B8. (b) NO release from 13 platelet extracts treated with 500 mM
B7. The triangles show samples treated in the same way but with a
10min preincubation with 500mM DTNB before addition of B7.
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entirely sGC independent and were altogether lost in PRP. The
release of NO from the furoxans was found to be critically
dependent on the presence of endogenous reducing agents. NO
generation was most striking in the presence of intracellular
levels of ascorbateþGSH, which acted synergistically to
release NO. By contrast, the nitrooxy ester, NCX4016, failed
to generate detectable NO in samples containing either
platelets or plasma.
Both the nitrooxy ester, NCX4016, and the furoxan–aspirin
hybrids were demonstrated to significantly inhibit COX-1. The
alterations to the chemical structure in the hybrids perhaps
play a role in bringing about the enhanced inhibition that was
observed compared to the unaltered aspirin compound. The
powerful inhibitory effect of the furoxan–aspirin hybrids in
the purified COX-1 assay, together with the equally powerful
effects of the furazan equivalents and the lack of significant
inhibition observed with the NO donor DEA/NO, suggests
that the COX-1-inhibitory activity of B8 and B7 is more likely
to be aspirin-mediated than NO-mediated. This assay demon-
strates that, in addition to their ability to inhibit platelet
aggregation via NO, the furoxan–aspirin hybrids retain an
aspirin-like action in vitro. At face value, these data would
indicate that any antiplatelet effects of the furoxan–aspirin
hybrids should be at least partially mediated by aspirin-
mediated inhibition of COX-1. However, it is important to
recognize that this effect might be lost in biological media or
in vivo, depending on how these compounds are hydrolysed
under physiologically relevant conditions. Previous studies
(Cena et al., 2003) have demonstrated complete hydrolysis of
the furoxan–aspirin acetyl group in serum. This feature would
suggest that in plasma, there is at least a partial loss of the
acetyl group, resulting in formation of the salicylic acid
equivalent. As salicylic acid was demonstrated to have no
effect in this assay of COX activity and failed to affect platelet
aggregation, modifications to the chemical structure to
improve retention of the acetyl group in plasma is likely to
be necessary to avoid loss of the COX-inhibiting effects of the
compounds. Other groups have also demonstrated that COX
inhibition by the hybrid NCX4016 has a similar requirement
for the acetyl group but not the NO moiety (Corazzi et al.,
2005).
The present study extends findings from preliminary
aggregation studies which have been published previously
(Cena et al., 2003). Here, we further investigated the relative
contribution of the NO- and aspirin moieties to the antiplatelet
effect. The furoxan–aspirin hybrid drugs inhibited platelet
aggregation in both WP and PRP, although the effects of both
compounds, and B7 in particular, were attenuated in PRP. The
comparatively weak inhibitory effects of the NO-free furazan
counterparts is indicative of a major role for NO in platelet
inhibition, while the inhibitory effect of ODQ confirmed that a
major component of the effects is sGC dependent, especially in
PRP. The impact of ODQ on responses was less pronounced in
WP, particularly in the case of B7, due in part to the greater
influence of NO-independent effects, as illustrated by in-
creased sensitivity of WP to the furazan counterparts of B7
and B8. The effects of the furazan derivatives were weak
compared to aspirin, but were nevertheless more potent than
salicylic acid under the conditions of these experiments. The
lower activity of these agents in PRP compared to WP is in
keeping with the complete hydrolysis of the furoxan–aspirin
acetyl group in serum (Cena et al., 2003), resulting in
formation of relatively ineffectual salicylic acid. These hybrid
molecules are likely to undergo hydrolysis at two positions:
firstly, at the acetyl group, converting aspirin to salicylic acid
and secondly at the other ester linkage to release the furoxan.
The order and rates at which hydrolysis occurs will greatly
influence the ability of these compounds to retain aspirin
activity.
The high levels of NO release by B8 and the loss of its
aspirin effect in PRP imply that its antiplatelet actions are
mainly NO mediated. By comparison, B7, which releases NO
more slowly, has an IC50 closer to that of aspirin. These
characteristics are more suitable for a NO–aspirin hybrid drug
because they provide potential for a more balanced action
between NO and aspirin antiplatelet effects. The unfortunate
loss of the aspirin effect in PRP, however, is an issue that needs
to be addressed by appropriate modification of the chemical
structure.
The finding that NCX4016 is an effective inhibitor of
platelet aggregation in WP is in keeping with previous in vitro
studies using NCX4016 (Lechi et al., 1996) and the related
drug, NCX4125 (Minuz et al., 1995; Wallace et al., 1995).
However, our results go on to show that the effect is lost in
PRP, possibly due to sequestration by a plasma constituent
such as albumin or due to breakdown in the plasma to the
inactive salicylic acid. Interestingly, the inhibitory effect of
NCX4016 was significantly enhanced compared to aspirin but
was not affected by the sGC inhibitor, ODQ. While a cGMP-
independent effect of NCX4016-derived NO cannot be ruled
out, our inability to detect NO generation from this
compound, coupled with the known inability of platelets to
effect NO release from organic nitrates (Weber et al., 1996),
and the COX assay data demonstrating powerful anti-COX
activity of NCX4016, suggests that the antiplatelet action of
NCX4016 is most likely NO independent. Although our study
shows NCX4016 to be a poor inhibitor of platelet function,
its effects in other cell types may still make it a useful
cardiovascular drug. Antiplatelet effects may still be retained
in vivo through remote nitrooxy-ester activation in cells other
than platelets (e.g. smooth muscle cells), although this would
appear to be a rather inefficient method of NO delivery
specifically to platelets. Nevertheless, antiplatelet effects of
NCX4016 have been demonstrated ex vivo, in animals and
humans (Wainwright et al., 2002; Fiorucci et al., 2003; 2004;
Momi et al., 2005). Furthermore, NCX4016 has beneficial
effects in vivo, where it has been demonstrated to protect the
vascular endothelium in diabetic rats (Pieper et al., 2002), to
reduce blood pressure in hypertensive rats (Muscara et al.,
2001), to prevent restenosis in hypercholesterolemic mice
(Napoli et al., 2001) and to reduce infarct size in a model of
cardiac ischaemia in pigs (Wainwright et al., 2002).
The furoxan drugs are very stable compounds that appear
only to decompose to release significant NO when they
encounter appropriate media. There was no release of NO
from the furoxans in Tyrode’s buffer, but NO generation was
detected in PPP, WP and PRP. These observations suggest
that some elements of plasma can stimulate decomposition of
the furoxans and that the platelets themselves enhance the
effect to a greater extent for B8 than B7.
The plasma components, albumin, glutathione and ascor-
bate, chosen for their reducing properties, were all found to
have a limited capacity to stimulate furoxan decomposition
to release NO. In the case of B7, these constituents could
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individually stimulate moderate NO release, and the additive
effect of all three could fully emulate NO release in PPP. The
effect of these constituents on B8 were similar, if less dramatic,
for the individual reducing agents, but here there was no
additive effect when coincubated, suggesting that an as yet
unidentified plasma constituent is responsible for a proportion
of NO release from B8.
Reconstitution of Tyrode’s buffer with intracellular levels of
GSH and ascorbate demonstrated that both these reducing
agents were mildly effective in stimulating release of NO from
the compounds. Interestingly, however, they acted synergisti-
cally in coincubation experiments to massively increase NO
generation. The separate experiments using platelet extracts
established that there was a relationship between the concentra-
tion of platelet extract and amount of NO generated from the
furoxans. The ability of platelet extracts to generate NO from
both furoxans was found to be dependent on the presence of
reduced thiol groups and, in keeping with our other NO release
data and the platelet aggregation experiments, B8 generated
considerably more NO in the 10min incubation period than B7.
Taken together, these results indicate that low-level decomposi-
tion of B7 in plasma can be explained by the additive effects
of albumin, GSH and ascorbate but that there is also likely to
be much greater NO release inside platelets mediated by the
synergistic action of ascorbate and reduced intracellular thiols.
B8 is more sensitive to the same agents, and its plasma
decomposition is also affected by an as yet unidentified plasma
component. Given the reactive nature of NO, the apparent
preferential release inside target cells is a likely advantage for
successful NO delivery over compounds that can only generate
NO remotely in cell types other than platelets.
Previous studies have shown that both furoxan–aspirins
(Cena et al., 2003) and NCX4016 (Fiorucci et al., 1999; 2003;
Fiorucci & Del Soldato, 2003) have a preferential gastro-
toxicity profile over aspirin, suggesting either a masking of the
toxic aspirin effect or an active NO element in the gastro-
intestinal tract. However, the activity of both the NO and
aspirin elements of the hybrids in platelets is questionable.
NCX4016 has no antiplatelet action in PRP, and in WP it fails
to demonstrate aspirin-independent effects, possibly due to
sequestration by a plasma constituent. Unlike NCX4016, the
furoxans demonstrate aspirin-independent effects on platelet
aggregation in both PRP and WP in vitro, but their ability
to retain the action of aspirin is compromised, particularly
in PRP. The furoxans appear to display a more effective
antiplatelet activity over NCX4016, but further molecular
modifications are necessary in an effort to retain the aspirin
actions, in addition to achieving the added benefits of NO.
In summary, furoxan–aspirin hybrids are stable antiplatelet
compounds, the decomposition of which is catalysed by
endogenous agents which may instil a potential for primarily
intracellular delivery of NO, on account of the differential
distribution of glutathione and ascorbate within cells com-
pared to plasma and extracellular fluid. While the furoxan
hybrid examples tested in these experiments carry a number of
limitations, they also highlight the therapeutic potential of
future exponents of this class of drugs.
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